Abnormalities of Inhibitory Neuronal Mechanisms in the Motor Cortex of Patients with Schizophrenia

 

 Buy Article Permissions and Reprints

Background: Focal transcranial magnetic stimulation (TMS) of the motor cortex was used to study two cortically activated inhibitory neuronal mechanisms that suppress ongoing tonic voluntary electromyographic activity in contralateral (postexcitatory inhibition [PI]) and ipsilateral (transcallosal inhibition [TI]) hand muscles. The PI follows the corticospinally mediated excitatory motor response (MEP) and is influenced by dopaminergic neurotransmission. TI reflects transcallosally mediated inhibition of the contralateral motor cortex, leading to motor inhibition in muscles ipsilateral to stimulation. PI and TI were studied to explore whether dopaminergic neurotransmission or interhemispheric transfers are altered in schizophrenia. Methods: TMS was performed in 16 patients with this disease and in 16 healthy control subjects. Surface electromyographic activity was recorded bilaterally from the first dorsal interosseous muscle during a sustained strong isometric contraction. Results: When compared with the findings in healthy subjects, patients with schizophrenia had a significantly longer PI and TI. The changes of the PI support the notion of an overactivity of the central dopaminergic system in schizophrenia. Conclusion: The prolonged TI suggests an abnormal activation of interhemispheric connections between the motor cortices and may be related to previously reported pathology of the corpus callosum in schizophrenic patients.

References

• 1 Abarbanel J M, Lemberg T, Yaroslavski U, Grisaru N, Belmaker R H. Electrophysiological responses to transcranial magnetic stimulation in depression and schizophrenia.  Biol Psychiat. 1996;  40 148-150
  PubMedGoogle Scholar
• 2 Angrist B M, Gershon S. The phenomenology of experimentally induced amphetamine psychosis-preliminary observations.  Biol Psychiat. 1970;  2 95-107
  PubMedGoogle Scholar
• 3 Barker A T, Jalinous R, Freeston I L. Non-invasive magnetic stimulation of human motor cortex.  Lancet. 1985;  1 1106-1107
  PubMedGoogle Scholar
• 4 Bogerts B, Falkai P, Haupts M, Greve B, Ernst S, Tapernon-Franz U. et al . Post-mortem volume measurements of limbic system and basal ganglia structures in chronic schizophrenics. Initial results from a new brain collection.  Schizophr Res. 1990;  3 295-301
  CrossrefPubMedGoogle Scholar
• 5 Boroojerdi B, Töpper R, Foltys H, Meincke U. Transcallosal inhibition and motor conduction studies in patients with schizophrenia using transcranial magnetic stimulation.  Br J Psychiatr. 1999;  157 375-379
  PubMedGoogle Scholar
• 6 Braff D L, Geyer M A. Sensorimotor gating and schizophrenia: Human and animal model studies.  Arch Gen Psychiat. 1990;  47 181-188
  PubMedGoogle Scholar
• 7 Breier A, Su T P, Carson R E, Kolachana B S, de Bartolomeis A, Weinberger D R. et al . Schizophrenia is associated with elevated amphetamine induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method.  Proc Natl Acad Sci USA. 1997;  94 2569-257
  CrossrefPubMedGoogle Scholar
• 8 Callicott J H, Bertolino A, Mattay V S, Langheim F J, Duyn J, Coppola R. et al . Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited.  Cerebral Cortex. 2000;  10 1078-1092
  CrossrefPubMedGoogle Scholar
• 9 Cantello R, Gianelli M, Civardi C, Mutani R M. agnetic brain stimulation: the silent period after the motor evoked potential.  Neurology. 1992;  42 1951-1959
  PubMedGoogle Scholar
• 10 Classen J, Benecke R. Inhibitory phenomena in individual motor units induced by transcranial magnetic stimulation.  Electroencephalogr Clin Neurophysiol. 1995;  97 264-274
  CrossrefPubMedGoogle Scholar
• 11 Coger R W, Serafetinides E A. Schizophrenia, corpus callosum, and interhemispheric communication: a review.  Psychiat Res. 1990;  34 163-184
  CrossrefPubMedGoogle Scholar
• 12 Coyle J T. The glutamatergic dysfunction hypothesis for schizophrenia.  Harv Rev Psychiat. 1996;  3 241-253
  PubMedGoogle Scholar
• 13 Cross A J, Crow T J, Owen F. 3H-Flupenthixol binding in post-mortem brains of schizophrenics: evidence for a selective increase in dopamine D2 receptors.  Psychopharmacology (Berl). 1981;  74 122-124
  CrossrefPubMedGoogle Scholar
• 14 Daskalakis Z J, Christensen B K, Chen R, Fitzgerald P B, Zipursky R B, Kapur S. Evidence for impaired cortical inhibition in schizophrenia using transcranial magnetic stimulation.  Arch Gen Psychiat. 2002;  59 347-354
  CrossrefPubMedGoogle Scholar
• 15 Davey N J, Puri B K, Lewis H S, Lewis S W, Ellaway P H. Effects of antipsychotic medication on electromyographic responses to transcranial magnetic stimulation of the motor cortex in schizophrenia.  J Neurol Neurosurg Psychiat. 1997;  63 468-473
  CrossrefPubMedGoogle Scholar
• 16 David A S. Schizophrenia and the corpus callosum: developmental, structural and functional relationships.  Behav Brain Res. 1994;  64 203-211
  CrossrefPubMedGoogle Scholar
• 17 Day B L, Thompson P D, Dick J P, Nakashima K, Marsden C D. Different sites of action of electrical and magnetic stimulation of the human brain.  Neurosci Lett. 1987;  75 101-106
  CrossrefPubMedGoogle Scholar
• 18 Del Arco A, Mora F. Endogenous dopamine potentiates the effect of glutamate on extracellular GABA in the prefrontal cortex of the freely moving rat.  Brain Res Bull. 2000;  53 339-345
  CrossrefPubMedGoogle Scholar
• 19 Endicott J, Spitzer R, Fleiss J, Cohen J. The Global Assessment Scale.  Arch Gen Psychiat. 1976;  33 766-771
  PubMedGoogle Scholar
• 20 Falkai P, Bogerts B, Rozumek M. Limbic pathology in schizophrenia: the entorhinal region - a morphometric study.  Biol Psychiat. 1988;  24 515-521
  PubMedGoogle Scholar
• 21 Ferbert A, Priori A, Rothwell J C, Day B L, Colebatch J G, Marsden C D. Interhemispheric inhibition of the human motor cortex.  J Physiol. 1992;  453 525-546
  CrossrefPubMedGoogle Scholar
• 22 Fitzgerald P B, Brown T L, Daskalakis Z J, Kulkarni J. A transcranial magnetic stimulation study of inhibitory deficits in the motor cortex in patients with schizophrenia.  Psychiat Res. 2002;  114 11-21
  PubMedGoogle Scholar
• 23 Fitzgerald P B, Brown T L, Daskalakis Z J, deCastella A, Kulkarni J. A study of transcallosal inhibition in schizophrenia using transcranial magnetic stimulation.  Schizophr Res. 2002;  56 199-209
  CrossrefPubMedGoogle Scholar
• 24 Fitzgerald P B, Brown T L, Daskalakis Z J, Kulkarni J. A transcranial magnetic stimulation study of the effects of olanzapine and risperidone on motor cortical excitability in patients with schizophrenia.  Psychopharmacology (Berl). 2002;  162 74-81
  CrossrefPubMedGoogle Scholar
• 25 Freedman R, Adler L E, Myles-Worsley M, Nagamoto H T, Miller C, Kisley M. , et al . Inhibitory gating of an evoked response to repeated auditory stimuli in schizophrenic and normal subjects. Human recordings, computer simulation and an animal model.  Arch Gen Psychiat. 1996;  53 1114-1121
  PubMedGoogle Scholar
• 26 Hoppner J, Kunesch E, Grossmann A, Tolzin C J, Schulz M, Schlafke D ,. et al . Dysfunction of transcallosally mediated motor inhibition and callosal morphology in patients with schizophrenia.  Acta Psychiat Scand. 2001;  104 227-235
  PubMedGoogle Scholar
• 27 Joyce J N, Lexow N, Bird E, Winokur A. Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Huntington's disease and schizophrenia.  Synapse. 1988;  2 546-557
  CrossrefPubMedGoogle Scholar
• 28 Kay S R, Fiszbein A, Opler L AT. he positive and negative syndrome scale (PANSS) for schizophrenia.  Schizophr Bull. 1987;  13 261-276
  CrossrefPubMedGoogle Scholar
• 29 Laruelle M, Abi-Dargham A, van Dyck C H, Gil R, D'Souza C D, Erdos J. , et al . Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.  Proc Natl Acad Sci USA . 1996;  93 9235-9240
  CrossrefPubMedGoogle Scholar
• 30 Masur H, Althoff S, Erim Y, Oberwittler C, Hornung W P. Postexcitatory inhibition after transcranial magnetic stimulation of the motor cortex in patients with drug-induced parkinsonism and in healthy individuals.  Int Clin Psychopharmacol. 1998;  13 79-82
  PubMedGoogle Scholar
• 31 McCormick D A. Neurotransmitter actions in the thalamus and cerebral cortex and their role in neuromodulation of thalamocortical activity.  Prog Neurobiol. 1992;  39 337-388
  CrossrefPubMedGoogle Scholar
• 32 Meyer B U, Kühn A, Röricht S, Kupsch A. Direct activation of corticospinal fibres at the level of the internal capsule in man.  Clin Neurophysiol. 2001;  12 (Suppl) S7
  PubMedGoogle Scholar
• 33 Meyer B U, Röricht S, Grafin von Einsiedel H, Kruggel F, Weindl A. Inhibitory and excitatory interhemispheric transfers between motor cortical areas in normal humans and patients with abnormalities of the corpus callosum.  Brain. 1995;  118 429-440
  PubMedGoogle Scholar
• 34 Meyer B U, Röricht S, Schmierer K, Irlbacher K, Meierkord H, Niehaus L. , et al . First diagnostic applications of transcallosal inhibition in diseases affecting callosal neurones (Multiple sclerosis, Hydrocephalus, Huntington's disease).  Electroencephalogr Clin Neurophysiol. 1999;  51 233-242
  PubMedGoogle Scholar
• 35 Meyer B U, Röricht S, Woiciechowsky C. Topography of fibers in the human corpus callosum mediating interhemispheric inhibition between the motor cortices.  Ann Neurol. 1998;  43 360-369
  CrossrefPubMedGoogle Scholar
• 36 Neumann M, Livak V, Paul H W, Laux G. Acute psychosis after administration of bupropion hydrochloride (Zyban).  Pharmacopsychiatry. 2002;  35 247-248
  Article in Thieme ConnectPubMedGoogle Scholar
• 37 Nordstrom A L, Farde L, Eriksson L, Halldin C. No elevated D2 dopamine receptors in neuroleptic-naive schizophrenic patients revealed by positron emission tomography and [11C]N-methylspiperone.  Psychiat Res. 1995;  61 67-83
  PubMedGoogle Scholar
• 38 Overall J E, Gorham D R. The Brief Psychiatric Rating Scale.  Psych Rep. 1962;  10 799-812
  CrossrefPubMedGoogle Scholar
• 39 Pakkenberg B. Post-mortem study of chronic schizophrenic brains.  Br J Psychiat. 1987;  151 744-752
  PubMedGoogle Scholar
• 40 Paya B, Guisado J A, Vaz F J, Crespo-Facorro B. Visual hallucinations induced by the combination of prolintane and diphenhydramine.  Pharmacopsychiatry. 2002;  35 24-25
  Article in Thieme ConnectPubMedGoogle Scholar
• 41 Priori A, Berardelli A, Inghilleri M, Accornero N, Manfredi M. Motor cortical inhibition and the dopaminergic system. Pharmacological changes in the silent period after transcranial brain stimulation in normal subjects, patients with Parkinson's disease and drug-induced parkinsonism.  Brain. 1994;  117 317-323
  PubMedGoogle Scholar
• 42 Puri B K, Davey N J, Ellaway P H, Lewis S W. An investigation of motor function in schizophrenia using transcranial magnetic stimulation of the motor cortex.  Br J Psychiat. 1996;  169 690-695
  CrossrefPubMedGoogle Scholar
• 43 Puri B K, Lewis S W. Transcranial magnetic stimulation in psychiatric research.  Br J Psychiatry. 1996;  169 675-677
  PubMedGoogle Scholar
• 44 Röricht S, Meyer B U, Woiciechowsky C, Lehmann R. Callosal and corticospinal tract function in patients with hydrocephalus: a morphometric and transcranial magnetic stimulation study.  J Neurology. 1998;  245 280-288
  PubMedGoogle Scholar
• 45 Rosenthal R, Bigelow L B. Quantitative brain measurements in chronic schizophrenia.  Br J Psychiat. 1972;  121 259-264
  PubMedGoogle Scholar
• 46 Rothwell J C. Physiological studies of electric and magnetic stimulation of the human brain.  Electroencephalogr Clin Neurophysiol. 1991;  43 (Suppl) 29-35
  PubMedGoogle Scholar
• 47 Schmidt K, Nolte-Zenker B, Patzer J, Bauer M, Schmidt L G, Heinz A. Psychopathological correlates of reduced dopamine receptor sensitivity in depression, schizophrenia, and opiate and alcohol dependence.  Pharmacopsychiatry. 2001;  34 66-72
  Article in Thieme ConnectPubMedGoogle Scholar
• 48 Schmierer K, Niehaus L, Röricht S, Meyer B U. Conduction deficits of callosal fibres in early multiple sclerosis.  J Neurol Neurosurg Psychiat. 2000;  68 633-638
  PubMedGoogle Scholar
• 49 Seeman P, Tallerico T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors.  Mol Psychiat. 1998;  3 123-134
  PubMedGoogle Scholar
• 50 Seeman P, Kapur S. Schizophrenia: more dopamine, more D2 receptors.  Proc Natl Acad Sci USA. 2000;  97 8104-8109
  CrossrefPubMedGoogle Scholar
• 51 Selemon L D, Goldman-Rakic P S. The reduced neuropil hypothesis: a circuit based model of schizophrenia.  Biol Psychiat. 1999;  45 17-25
  Google Scholar
• 52 Shenton M E, Dickey C C, Frumin M, McCarley R W. A review of MRI findings in schizophrenia.  Schizophr Res. 2001;  49 1-52
  Google Scholar
• 53 Simpson G M, Angus J W S. A rating scale for extrapyramidal side effects.  Acta Psychiatr Scand. 1970;  212 (Suppl.) 11-9
  PubMedGoogle Scholar
• 54 Valzania F, Strafella A P, Quatrale R, Santangelo M, Tropeani A, Lucchi D ,. et al . Motor evoked responses to paired cortical magnetic stimulation in Parkinson's disease.  Electroencephalogr Clin Neurophysiol. 1997;  105 37-43
  CrossrefPubMedGoogle Scholar
• 55 van Rossum J M. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs.  Arch Int Pharmacodyn Ther. 1966;  160 492-494
  PubMedGoogle Scholar
• 56 Werhahn K J, Kunesch E, Nochtar S, Benecke R, Classen J. Differential effects on motorcortical inhibition induced by blockade of GABA uptake in humans.  J Physiol 199. ;  517 591-597
  PubMedGoogle Scholar
• 57 Wong D F, Wagner H NJ, Tune L E, Dannals R F, Pearlson G D, Links J M,. et al . Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics.  Science. 1986;  234 1558-1563
  PubMedGoogle Scholar
• 58 Zakzanis K K, Hansen K T. Dopamine D2 densities and the schizophrenic brain.  Schizophr Res. 1998;  32 201-206
  CrossrefPubMedGoogle Scholar
• 59 Ziemann U, Tergau F, Bruns D, Baudewig J, Paulus W. Changes in human motor cortex excitability induced by dopaminergic and anti-dopaminergic drugs.  Electroencephalogr Clin Neurophysiol. 1997;  105 430-437
  CrossrefPubMedGoogle Scholar

Dr. Malek Bajbouj

Labor für Klinische Psychophysiologie

Department of Psychiatry

Freie Universität Berlin

Eschenallee 3

14050 Berlin

Germany

Phone: +49 30 8445 8622

Fax: +49 30 8445 8393

Email: malek.bajbouj@medizin.fu-berlin.de